NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · USD

Tevogen Inc. (TVGNW) Stock Analysis

Tevogen Inc. (TVGNW) is a stock listed on NASDAQ and quoted in US Dollar.

TVGNW

$0.05

+$0.00 (+1.36%)

Sep 4, 2026 · Market close

This is a derivative instrument — a warrant on Tevogen Bio Holdings Inc. (TVGN) common stock.

Issuer fundamentals are shown on the issuer page, not here.

View TVGN →

Price History

Hover for the daily close. The dotted line marks the period open.

TVGNW Key Statistics

As of Sep 4, 2026
Trading
Open
$0.05
Previous Close
$0.05
Day's Range
0.05–0.05
52-Week Range
0.05–0.05
Volume
225.17K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.19

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TVGNW Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+18.14%
2025 (partial year)+0.00%

As of September 4, 2026.

About Tevogen Inc.

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.

Visit website →